Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients

Hum Immunol. 2020 Dec;81(12):671-674. doi: 10.1016/j.humimm.2020.09.003. Epub 2020 Oct 9.

Abstract

Non-human leukocyte antigen (HLA) antibodies have been implicated in heart transplantation rejection. However, targets of non-HLA antibodies remain elusive. Here, we utilized a panel of multiplex beads-based assay to determine the specificity of non-HLA antibodies following heart transplantation. We utilized a selected cohort of recipients who did not have HLA donor specific antibodies, but were diagnosed with antibody mediated rejection and treated for antibody mediated rejection. We found the presence of vimentin antibody was associated with treated antibody mediated rejection. Our results suggest that, in heart transplant recipients who are suspected of AMR but in the absence of HLA donor specific antibodies, non-HLA antibodies should be examined.

Keywords: Antibody; HLA; Non-HLA; Rejection; Transplant.

MeSH terms

  • Adult
  • Aged
  • Autoantibodies / adverse effects*
  • Female
  • Follow-Up Studies
  • Graft Rejection / diagnosis
  • Graft Rejection / immunology*
  • Graft Rejection / therapy*
  • Graft Survival / immunology
  • HLA Antigens / immunology*
  • Heart Transplantation / adverse effects*
  • Histocompatibility Antigens Class I / immunology
  • Histocompatibility Antigens Class II / immunology
  • Histocompatibility Testing / methods
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Immunotherapy / methods*
  • Male
  • Middle Aged
  • Tissue Donors
  • Transplant Recipients*
  • Treatment Outcome
  • Vimentin / immunology*

Substances

  • Autoantibodies
  • HLA Antigens
  • Histocompatibility Antigens Class I
  • Histocompatibility Antigens Class II
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • VIM protein, human
  • Vimentin